-
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for the treatment of erectile dysfunction in men. Vardenafil joins sildenafil (Viagra) as the only 2 drugs approved for this indication in this country.
-
Drs. Gregg Stone and Stephen Ellis presented the 9-month clinical and angiographic results from TAXUS IV, which was designed to assess the safety and efficacy of the TAXUS slow-release polymer-based paclitaxel-eluting Express2 stent (Boston Scientific) in a broad cross-section of patients.
-
Sertraline contributed to a decrease in platelet activation over and above either aspirin or thienopyridines, and the SSRI might represent an attractive additional advantage for patients with depression and comorbid coronary artery disease and stroke.
-
The 3 CHARM studies (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) and their combined results were presented at the ESC meeting and published in Lancet in September.
-
The European Trial of Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) study tested the hypothesis that perindopril in patients with stable coronary artery disease, but without heart failure or substantial hypertension, will reduce cardiovascular deaths, myocardial infarction, and cardiac arrest.
-
The intracoronary stenting with antithrombotic Regimen Cooling Off (ISAR-COOL) study results were initially presented at the 2002 American
Heart Association Scientific Session.
-
Hylek and colleagues report on the effects of varying intensities of oral anticoagulation on the frequency and severity of strokes among patients with atrial fibrillation.
-
Insulin Plus Metformin vs Triple Oral Therapy in Type 2 Diabetes; ARB
and ACE-I in Diabetic Nephropathy; Low-Glycemic Index Diets and
Diabetes; Ultralow-Dose Estrogen and Bone in Older Women; Effect of
Intensity of Oral Anticoagulation in Atrial Fibrillation; Patient
Knowledge and Awareness of Hypertension
-
A generic form of paroxetine (PaxilGlaxoSmithKline) will soon be on the market. The drug marks the second SSRI antidepressant to go generic after fluoxetine (Prozac) last year.
-
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction.
